MMP-2、MMP-7、MMP-9、TIMP-1及TIMP-2在乳腺癌组织中的表达及意义

目的:探讨基质金属蛋白酶及其抑制剂在乳腺癌组织中的表达及其与肿瘤浸润转移的关系,为乳腺癌的临床治疗及预后预测提供基础。方法:选择我院2012年5月至2014年5月收治的乳腺癌患者80例,对所选病例的乳腺癌组织、癌旁组织及正常乳腺组织样本进行检测。观察并比较不同乳腺组织中MMP-2,MMP-7、MMP-9、TIMP-1及TIMP-2 m RNA的表达水平。结果:与正常乳腺组织相比较,乳腺癌组织和癌旁组织中MMP-2、MMP-7、MMP-9,TIMP-1及TIMP-2 m RNA的表达显著增加,差异具有统计学意义(P0.05)。乳腺癌组织中MMP-2、MMP-7、MMP-9、TIMP-1及TIMP-2 m RNA的表达显著高于癌旁组织和正常组织,差异具有统计学意义(P0.05)。随着肿瘤范围扩大,MMP-2、MMP-7和MMP-9 m RNA的表达水平显著增加(P0.05),而TIMP-1和TIMP-2 m RNA表达无显著变化(P0.05)。随着淋巴结转移进展,MMP-2、MMP-7和MMP-9 m RNA的表达显著增加(P0.05),而TIMP-1和TIMP-2 m RNA无显著变化(P0.05)。结论:MMP-2、MMP-7、MMP-9、TIMP-1和TIMP-2的m RNA在乳腺癌组织中呈高表达,这可能与乳腺癌的发生和发展有关,而MMP-2、MMP-7和MMP-9可能有助于预测乳腺癌的侵袭行为。     

基质金属蛋白酶-9及其抑制剂mRNA在吸烟大鼠肺组织中的表达

目的 研究吸烟大鼠肺组织和肺泡巨噬细胞中基质金属蛋白酶9(MMP-9)和金属蛋白酶组织抑制剂-1(TIMP-1)基因的表达,探讨其在细胞外基质重塑中的作用。方法 建立吸烟大鼠模型,随机分为对照组和吸烟1、2、3、4、5及6月组(每组10只),用原位杂交技术检测肺组织和肺泡巨噬细胞MMP-9和TIMP-1 mRNA表达,用免疫组织化学技术观察Ⅳ型胶原在肺内的表达。结果 吸烟组肺组织和肺泡巨噬细胞MMP-9 mRNA的表达逐渐上升,至吸烟6月时均达高峰;而TIMP-1 mRNA的表达渐上升,至吸烟3～4月时达高峰,后逐步下降;肺组织Ⅳ型胶原的表达在吸烟3月时达高峰,然后渐降。结论 MMP-9／TIMP-1的动态平衡在吸烟大鼠肺气肿模型肺组织的细胞外基质重塑中有重要作用。     

基质金属蛋白酶和组织金属蛋白酶抑制剂在肾细胞癌组织中的表达

目的:基质金属蛋白酶及组织金属蛋白酶抑制剂在肾细胞癌转移中占有重要的作用,研究肾细胞癌组织中MMP-2、MMP-9、TIMP-1和TIMP-2的表达情况,为肾癌转移的治疗提供理论依据。方法:选取36例肾细胞癌肾组织标本,从相同的肾细胞癌组织及癌旁肾组织获得对照样本,均进行根治性肾切除手术切除。肿瘤分期按TNM分期标准。为了统计评估,肿瘤1期和2期为低级,3期以上为高级。RT-PCR检测肿瘤和正常组织中的MMP-2、MMP-9、TIMP-1和TIMP-2的表达。结果:不同样本MMPs和TIMPs表达水平各不相同。肾细胞癌组织中MMP-2、MMP-9、TIMP-1、TIMP-2在肾细胞癌中的表达明显高于正常肾组织(P0.05)。在肾细胞癌的肿瘤分期方面,MMP-2与MMP-9和肿瘤的分期显著相关,随着肿瘤分期的增加,MMP-2与MMP-9的表达明显升高(P0.05),而TIMP-1与TIMP-2与肿瘤的分期无关。结论:肾细胞癌组织中TIMP-2、MMP-2,MMP-9,TIMP-1的mRNA表达显著高于正常肾组织,抑制MMPS的表达将成为治疗肾细胞癌转移的新的方向。     

胃癌组织中MMP-7和TIMP-1的表达及意义

目的:探讨基质金属蛋白酶-7(MMP-7)及其组织抑制剂-1(TIMP-1)与胃癌发生发展的关系.方法:采用免疫组化技术检测46例胃癌组织和相应癌旁组织中MMP-7和TIMP-1的表达,结合病人临床病理资料进行综合分析.结果:胃癌组织中MMP-7阳性表达率(60.87%)显著高于相应癌旁组织,差异有统计学意义(P<0.05);其表达与淋巴结转移(P<0.05)相关.胃癌组织中TIMP-1的阳性表达率(93.48%)明显高于相应癌旁组织(63.04%),差异有统计学意义(P<0.05);其表达与淋巴结转移相关(P<0.05).结论:MMP-7与胃癌的侵袭转移有关,TIMP-1有可能成为评价胃癌恶性生物学行为的指标.     

己酮可可碱对肺纤维化大鼠MMP-2和TIMP-1表达的影响

目的观察己酮可可碱(pentoxifylline, PTX)对博来霉素致肺纤维化大鼠肺组织基质金属蛋白酶2(matrix metalloproteinase-2)和基质金属蛋白酶组织抑制剂1(tissue inhibitor of matrix metalloproteinase-1)表达的影响,初步探讨其抗肺纤维化的作用机制.方法 SD大鼠36只,随机分为模型组、治疗组和对照组.模型组和治疗组气管内注射博来霉素诱导肺纤维化,对照组在相同条件下给予生理盐水.第二天起治疗组大鼠腹腔给予己酮可可碱6mg/kg.d,其余两组相同条件下给予生理盐水.治疗的第7d和28d,处死动物取出肺组织,用RT-PCR和免疫组化ABC法观察各组鼠肺组织MMP-2和TIMP-1表达的变化. 结果与模型组比较,治疗组经PTX作用的第7d和28d肺组织中MMP-2和TIMP-1 mRNA的基因转录均有减少,MMP-2 mRNA表达分别降低33.4%和35.5%(P＜0.001),TIMP-1 mRNA表达分别降低25.3%和33.0%(P＜0.05).免疫组化结果则显示,PTX作用的第7d和28dMMP-2分别较模型组降低30.7%和41.7%(P＜0.05),TIMP-1分别降低13.1%和19.8%(P＜0.05).结论 PTX对肺纤维化不同时期肺组织中MMP-2和TIMP-1的表达均有一定程度的降低作用,其可能通过调整MMP-2和TIMP-1比值使其趋于平衡,从而延缓甚至抑制纤维化的进程.     

机械性去负荷后心室明胶酶及其组织型抑制剂与细胞外基质变化

目的：探讨左心室在去除压力和容量负荷下心室组织基质金属蛋白酶-2和-9及金属蛋白酶组织型抑制剂-1和-2表达水平与细胞外基质沉积量的关系。方法：12周龄雄性Lewis大鼠建立Lewis-to-Lewis腹腔异位心脏移植模型,形成左心室去负荷状态,并以同龄雄性Lewis大鼠胸腔原位心脏作为对照。移植后14d采用天狼猩红-偏振光法对移植和对照组心脏的ECM沉积量进行分析。心室组织MMP-2和MMP-9活性检测采用明胶酶谱法。MMP-2、MMP-9、TIMP-1、TIMP-2的mRNA表达水平检测采用荧光定量PCR法;TIMP-1和TIMP-2蛋白含量采用Western blot测定。结果：手术后14d,与原位心脏比较,腹腔移植心脏心肌细胞横截面积减小,并伴有心肌ECM沉积量增多（胶原容积分数5．22％±1．6％VS2．21％±0．9％,P〈0．05）,并且MMP-2、MMP-9明胶酶活性明显增强,MMP-2、MMP-9及其组织型抑制剂T1MP-1、TIMP-2的mRNA表达均增加（P〈0．05）,但TIMP-1、TIMP-2增加幅度较MMP-2、MMP-9高,TIMP-1、TIMP-2的蛋白含量均增加（P〈0．05）,TIMP-1增加幅度更为明显。结论：左心室在去除压力和容量负荷状态下心脏心室组织胶原沉积量增加,伴有MMPs／TIMPs系统失衡,尤其是TIMPs系统的明显上调。     

COPD大鼠模型气道MMP-9和TIMP-1表达的研究

目的:探讨基质金属蛋白酶-9(MMP-9)及组织金属蛋白酶抑制因子-1(TIMP-1)在慢性阻塞性肺疾病(COPD)大鼠模型气道的表达.方法:Wistar大鼠25只随机分为COPD模型组和正常对照组,采用单纯被动吸烟法建立COPD大鼠模型,以酶联免疫吸附法(ELISA)测定两组大鼠血清及支气管肺泡灌洗液(BALF)中MMP-9和TIMP-1的表达水平.结果:COPD组血清及BALF中MMP-9和TIMP-1的表达明显高于正常组(P＜0.05和P＜0.01);COPD组血清及BALF的MMP-9/TIMP-1低于正常组血清及BALF的MMP-9/TIMP-1,差异有统计学意义(P＜0.05);COPD组和正常组BALF中MMP-9和TIMP-1水平高于血清中MMP-9和TIMP-1水平,但差异无统计学意叉(P＞0.05).结论:MMP-9和TIMP-1平衡失调参与了COPD的发病,调节MMP-9和TIMP-1的平衡可能是治疗COPD的新方法.     

基质金属蛋白酶-2、-9及其组织抑制剂-1在大鼠肺组织中的增龄变化

目的研究基质金属蛋白酶（MMPs）-2、-9及组织型基质金属蛋白酶抑制剂（TIMPs）-1在大鼠肺组织中的增龄性变化规律。方法不同月龄（1月龄、3月龄、12月龄、18月龄、24月龄）雄性清洁级（SD）大鼠47只分为5组,按月龄取实验大鼠的右下叶肺组织,用流式细胞术检测MMP-2、MMP-9及TIMP-1的表达水平,进行定量分析。结果 MMP-2、MMP-9和TIMP-1均随着月龄的增长呈先降后升波谷型曲线变化;3月龄、12月龄和18月龄MMP-2、MMP-9和TIMP-1均较1月龄明显下降,且以12月龄为最低值;24月龄MMP-2、MMP-9和TIMP-1均较1月龄上升。MMP-2/TIMP-1比值和MMP-9/TIMP-1比值均随着月龄的增长呈先升后降波峰型曲线变化;12月龄和18月龄均较1月龄明显升高,且以18月龄为最高点;3月龄的MMP-2/TIMP-1较1月龄有所上升,3月龄的MMP-9/TIMP-1与1月龄持平;24月龄的MMP-2/TIMP-1和MMP-9/TIMP-1较1月龄也有不同程度上升。结论大鼠肺组织中MMPs及其抑制剂TIMPs随月龄的增长,呈特征性变化规律。     

MMP-2, -9, -14及其抑制剂TIMP-1, -2, -3在恒河猴周期黄体中的时空表达

用原位杂交和免疫组织化学方法研究了基质金属蛋白酶MMP-2, -9, -14及其组织抑制因子TIMP-1, -2, -3在恒河猴周期黄体发育不同阶段的协同表达. 结果显示: MMP-2 mRNA及其蛋白主要表达在早中期发育黄体的内皮细胞上, 在晚期黄体发生萎缩时则大量表达于黄体细胞; MMP-9, -14及其TIMP-1, -2, -3主要表达于黄体细胞; MMP-14 mRNA在早期和晚期黄体中高表达, MMP-9蛋白只在晚期黄体中高表达; TIMP-3蛋白在早、中、晚三期黄体中表达均较高, 但很明显晚期表达降低. 结果提示: MMP/TIMP系统参与灵长类黄体发育的调控, MMP-2, -14及其TIMP-1, -3可能参与黄体的形成和功能维持, 同时MMP-2, -9, -14及其TIMP-1, -2, -3在黄体萎缩期的协同表达, 提示它们可能在黄体发生萎缩时发挥作用.     

肝母细胞瘤组织RECK及膜型基质金属蛋白酶-1的表达及与肿瘤转移抑制关系的探讨

目的:探讨RECK蛋白、膜型基质金属蛋白酶-1(MT1-MMP)在肝母细胞瘤组织中的表达及其在肿瘤转移抑制中的作用。方法:采用第二代通用型二步法监测系统(PV-6000)免疫组织化学方法检测35例肝母细胞瘤组织和15例正常肝脏组织及10例肝脏良性肿瘤组织中RECK、MT1-MMP的表达情况。结果:肝母细胞瘤组织RECK的表达水平明显降低(28.6%);MT1-MMP肝母细胞瘤组织中高表达(54.3%),并随着肿瘤浸润深度的加深、远处转移的发生而增高(p<0.05);二者表达呈负相关(p<0.05)。结论:RECK和MT1-MMP在肝母细胞瘤组织中的表达呈负相关;RECK和MT1-MMP在肝母细胞瘤的进展中起重要作用。     

Clinical relevance of cyclooxygenase-2 and matrix metalloproteinases (MMP-2 and MT1-MMP) in human breast cancer tissue

Breast cancer (BC) is the most common neoplasm among women in most developed countries, including Egypt. Elevated levels of certain proteins in human BC are associated with unfavorable prognosis and progressive stages of the disease. The aim of our study was to evaluate the protein expression profile and prognostic significance of cyclooxygenase-2 (COX-2), matrix metalloproteinase-2 (MMP-2), MMP-9 and membrane type 1-MMP (MT1-MMP) and their interaction in operable BC patients. The protein expression of COX-2, MMP-2 and MT1-MMP were evaluated by western blot technique, whereas enzymatic activity of MMP-2 and MMP-9 was determined by zymography in 47 breast cancer patients as well as normal adjacent tissues. Also, the correlation between these proteins and age, tumor size, LN stage, TNM stage, estrogen receptor, progesterone receptor, disease-free survival, and overall survival (OS) has been investigated. As compared to adjacent normal tissues, COX-2, MMP-2 and MT1-MMP were over-expressed in 43, 64, and 60 % of tumor tissues, respectively. In the same pattern, the activity of MMP-2 (62 %) and MMP-9 (45 %) was elevated in BC tissues. Multivariate analysis showed a positive correlation between the protein expression of COX-2, MMP-2, and MT1-MMP and the activity of MMP-2 and MMP-9 in BC patients. However, the enzymatic activity showed no correlation with clinicopathological features. This study confirms the preclinical evidence that COX-2 increased the expression of MT1-MMP, which in turn activates MMP-2. The lack of correlation with clinicopathological features, OS or disease-free survival ascertains the complexity of tumor progression and metastasis with many pro- and counter regulatory factors.     

Expression of gelatinases A and B and their endogenous regulators in immortal and transformed fibroblasts

Matrix metalloproteinases (MMP) play a critical role in tumor invasion and metastasis. The goal of this study was to elucidate peculiarities of expression of gelatinases A and B (MMP-2 and MMP-9), membrane type MMP (MT1-MMP) and tissue inhibitor of MMP (TIMP-2) in immortal (IF) and transformed fibroblasts (TF). The study was carried out using embryo rat fibroblasts, sequentially immortalized with the polyomavirus LT gene and transformed with the E7 gene of human papillomavirus (HPV-16). Papillomaviruses type16 and 18 are the etiological factor for cervical cancer. A primary fibroblast (PF) culture of Fisher rats was used as control. Analysis of TF and IF included determination of MMP-2 and MMP-9 activity by hydrolysis of the specific substrate, radioactive collagen type IV; analysis of MMP spectra by a zymographic assay, and estimation of the mRNA expression by RT-PCR. It was found that: (1) collagenolytic activity of MMP was increased only in TF and it depended on the degree of cell tumorigenicity; (2) the study of MMP spectra revealed the presence of MMP-9 only in TF, whereas MMP-2 was found in IF as well; (3) the mRNA expression of MMP-9, MT1-MMP and TIMP-2 increased in all TF while the MMP-2 expression increased in TF only after TF cell selection on rats; (4) the collagenolytic activity as well as the mRNA expression of MMP-2 and MMP-9 and endogenous regulators (MT1-MMP and TIMP-2) did not change in immortalized fibroblasts compared to the PF culture. The data obtained indicate changes in the ratio enzyme/activator/inhibitor and also suggest a significant increase in the TF destructive potential. MMP-9 is supposed to be a marker of fibroblasts transformed by E7 HPV16 gene in a cell culture.     

Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables

The balance between matrix metalloproteinases (MMPs) and their physiological tissue inhibitors of matrix metalloproteinases (TIMPs) is crucial in tumour invasion and progression. The aim of this study was to investigate the levels of MMP-9, MMP-3 and TIMP-1 in colorectal cancer (CRC) and to evaluate these proteinases and their inhibitor with respect to clinicopathological variables. Activities of pro- and active MMP-9 were measured in paired tumour and distant normal tissue specimens from 43 patients with CRC using gelatin zymography. ELISA was employed for the determination of MMP-9, MMP-3 and TIMP-1 protein expressions. The activity levels of pro- and active MMP-9 and protein expression levels of MMP-9, MMP-3 and TIMP-1 were higher in tumour tissues than in the corresponding normal tissues; the differences being significant for all (p < 0.05), except TIMP-1. Similarly, active MMP-9/proMMP-9 and the ratio of protein expression level of MMP-9-TIMP-1 were found to be significantly higher in tumour tissues ( p < 0.01). Among all the clinicopathological variables investigated, significant correlations were found between MMP-9 and presence of perineural invasion, MMP-3 and lymph node status, TIMP-1 and tumour differentiation, MMP-9/TIMP-1 ratio and histological types ( p < 0.05). In conclusion, MMP-3 was not as notably increased as MMP-9 in tumour tissues. However, different roles may be attributed to MMP-9 and MMP-3 in CRC development and progression. Additionally, assessment of TIMP-1 in relation to MMPs appeared to be crucial in CRC studies to provide a basis for the re-evaluation of the clinical usefulness of TIMP-1 in colorectal cancer.     

Dermal fibroblasts from pseudoxanthoma elasticum patients have raised MMP-2 degradative potential

Cultured fibroblasts from the dermis of normal subjects and of Pseudoxanthoma elasticum (PXE) patients were analysed for enzyme activity, protein and mRNA expression of metalloproteases (MMP-2, MMP-3, MMP-9, MT1-MMP) and of their specific inhibitors (TIMP-1, TIMP-2 and TIMP-3). MMP-3, MMP-9 and TIMP-3 mRNAs and proteins failed to be detected in both the medium and the cell layer of both controls and PXE patients. MMP-2 mRNA was significantly more expressed in PXE than in control cell lines, whereas MT1-MMP, TIMP-1 and TIMP-2 mRNAs appeared unchanged. MMP-2 was significantly higher in the cell extracts from PXE fibroblasts than in control cells, whereas differences were negligible in the cell medium. Data suggest that PXE fibroblasts have an increased proteolytic potential, and that MMP-2 may actively contribute to connective tissue alterations in this genetic disorder.     

Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors

The tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of the matrix metalloproteinases (MMPs). Since unregulated MMP activities are linked to arthritis, cancer, and atherosclerosis, TIMP variants that are selective inhibitors of disease-related MMPs have potential therapeutic value. The structures of TIMP/MMP complexes reveal that most interactions with the MMP involve the N-terminal pentapeptide of TIMP and the C-D beta-strand connector which occupy the primed and unprimed regions of the active site. The loop between beta-strands A and B forms a secondary interaction site for some MMPs, ranging from multiple contacts in the TIMP-2/membrane type-1 (MT1)-MMP complex to none in the TIMP-1/MMP-1 complex. TIMP-1 and its inhibitory domain, N-TIMP-1, are weak inhibitors of MT1-MMP; inhibition is not improved by grafting the longer AB loop from TIMP-2 into N-TIMP-1, but this change impairs binding to MMP-3 and MMP-7. Mutational studies with N-TIMP-1 suggest that its weak inhibition of MT1-MMP, as compared to other N-TIMPs, arises from multiple (>3) sequence differences in the interaction site. Substitutions for Thr2 of N-TIMP-1 strongly influence MMP selectivity; Arg and Gly, that generally reduce MMP affinity, have less effect on binding to MMP-9. When the Arg mutation is added to the N-TIMP-1(AB2) mutant, it produces a gelatinase-specific inhibitor with Ki values of 2.8 and 0.4 nM for MMP-2 and -9, respectively. Interestingly, the Gly mutant has a Ki of 2.1 nM for MMP-9 and >40 muM for MMP-2, indicating that engineered TIMPs can discriminate between MMPs in the same subfamily.